Navigation Links
Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer
Date:7/1/2008

Ability to Perform Testing on Biopsy-sized Specimens Allows for Greater

Clinical Utility in all Breast Cancer Settings

PITTSBURGH, July 1 /PRNewswire/ -- Precision Therapeutics Inc. announced today that results from the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlate with pathologic complete response in breast cancer patients treated with neoadjuvant (pre-operative) chemotherapy. Data published in Anticancer Research show that the assay accurately predicted response to therapy 75% of the time. This study, done in conjunction with US Oncology, a leading cancer research and treatment network, represents the company's first publication in the breast cancer setting.

"Achieving pathologic complete response is an important goal for patients in the neoadjuvant breast cancer setting. Precision Therapeutics' data demonstrate that ChemoFx has the potential to predict which chemotherapy regimens will be most effective, thus potentially sparing patients from unnecessary toxicity associated with ineffective treatment," said Joyce O'Shaughnessy, MD, of Baylor-Sammons Cancer Center in Dallas and associate study investigator. Ongoing definitive trials are evaluating whether the promising results from our study with ChemoFx will help us design more personalized pre-operative treatment strategies."

Other major findings of the study addressed technical aspects of the assay, including the feasibility of performing the test on small amounts of tissue and the reproducibility of test results. The study demonstrated that the test could be successfully performed 84% of the time on tissue samples as small as 35 mg (2 14 gauge core needle biopsies). This finding is significant because historically chemoresponse assays have been limited by the need for a large amount of tissue (1-5 grams). The small tissue requirement demonstrated in this study is crucial in the breast c
'/>"/>

SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Two studies published in the Lancet
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. New report on mobile phone research published
5. 2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available
6. Meta-Analysis of Blood Phe Levels and Clinical Outcomes in PKU Published
7. Clinical Study Published Showing Benefits of Glue Used in Facelift Surgery
8. New tool to assess excessive daytime sleepiness in adolescents published in JCSM
9. Published Results Using AtriCure Minimally Invasive Products
10. Mirixa Debuts RxFYI - a Free Pharmacy-Published Health eNewsletter Building Patient Loyalty and Generating Revenue
11. Long Term Care Newsletter Debuts, Published by LTC Financial Partners; Advice on Living Better, Not Just Longer, With Financial Protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye Health Plan is reminding ... immunizations are covered for members under the Healthchek program . , “Many ... with their immunizations may not be allowed to attend when school begins in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... law firms and government entities, today announced that John Munro, a 15-year veteran ... Vice President of Managed Services Operations. , “I am thrilled to join Discovia ...
(Date:8/4/2015)... St. Louis, Missouri (PRWEB) , ... August 04, ... ... Automated Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership ... 30-year track record of sales success at technology companies and expanding global markets ...
(Date:8/4/2015)... ... 04, 2015 , ... Mesothelioma researchers in Australia have some ... be a viable option. Surviving Mesothelioma has just posted an article on the ... at the University of New South Wales, peritoneal mesothelioma patients can ...
(Date:8/4/2015)... ... 04, 2015 , ... T.E.N., an information technology and security executive networking and ... Den and Jungle Lounge 2015, which will be held from 3-6:30 p.m. Aug. 5 ... eight emerging security vendors, known as “Gazelles,” will go head-to-head with the ISE® Lions, ...
Breaking Medicine News(10 mins):Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4
... increase in the death rates, from the combination of HIV ... of South Africa//. ,Western Cape tops for ... 2003 made TB is the biggest cause of mortality in ... people are to be warned about the dreaded conditions behind ...
... to a recent study, an old drug promises to slow ... systemic sclerosis//. ,About 3,00,000 Americans were found ... our system by hardening and thickening the skin and in ... organs. Nearly 80% of affected people have lung damaged more ...
... Germany have announced progress in their collaborative research ... treatment of hemophilia. ,Extensive in vitro ... lead molecules with promising pharmacological properties. ... make important progress in our collaboration with Baxter, ...
... by polio and as of now 15 people have ... mass vaccination campaign to fight polio. // This campaign ... permanent secretary in the health ministry. On the whole ... in the southern African country. Namibian President Hifikepunye Pohamba, ...
... // ,Pathology labs in the city have registered an increase ... ,Rajesh Bose (name changed) got an HIV test done last ... parents thought I was a flirt," said Bose. "But when I produced ... ,Not only men but prospective brides too are going in for HIV ...
... annual conference of the European Society of Human Reproduction ... //are comfortable with the thought of having twins via ... found that they were often not aware of the ... we have been alarmed by the large numbers of ...
Cached Medicine News:Health News:Advance in Program for Development of Non-Intravenous Therapy for Hemophilia 2Health News:Advance in Program for Development of Non-Intravenous Therapy for Hemophilia 3
(Date:8/3/2015)... 3, 2015 Discovery Laboratories, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... at 8:30 a.m. Eastern Time on Tuesday August 11, ... 2015 second quarter financial results along with providing ... press release announcing the second quarter 2015 financial ...
(Date:8/3/2015)... REDWOOD CITY, Calif., Aug. 3, 2015 AcelRx ... company focused on the development and commercialization of innovative ... a business update and reported financial results for the ... Business highlights include: , On July 23, ... (CHMP) adopted a positive opinion for Zalviso™ for the ...
(Date:8/3/2015)... FLINT, Mich., Aug. 3, 2015 Diplomat Pharmacy, Inc. ... announced financial results for the quarter ended June 30, 2015. ... June 30, 2014. Second Quarter 2015 Highlights ... of 49% or $266 million , Total prescriptions dispensed ... of 8.6% versus 5.5% , Adjusted EBITDA of $22.7 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... July 19, 2011 Spanish drug companies face a ... the United States.  From regulatory (FDA) and GMP compliance, ... there are many areas that must be coordinated.  Those ... company KIM and U.S. company VPCI have entered into ...
... July 19, 2011 Reportlinker.com announces that ... in its catalogue: The ... Discovery http://www.reportlinker.com/p0574968/The-Changing-Role-of-Natural-Products-in-Drug-Discovery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ... This report reveals how natural products have ...
Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2The Changing Role of Natural Products in Drug Discovery 2The Changing Role of Natural Products in Drug Discovery 3The Changing Role of Natural Products in Drug Discovery 4
... Helmer presents the i.Series ... innovative solutions for the ... sophisticated features than ever ... Refrigerators are at the ...
... the i.Series refrigerator iB120, ... for the blood bank. ... than ever before, i.Series ... at the forefront of ...
... for the precise requirements of blood ... Blood Bank Equipment meets American Association ... Red Cross (ANRC) and U.S. Food ... storage freezers, and platelet incubators feature ...
The TBR-360-1-GD is a large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standar...
Medicine Products: